Dyadic Applied BioSolutions And BRIG BIO Signs Development And Commercialization Agreement To Jointly Develop And Commercialize Recombinant Bovine Alpha-Lactalbumin

Dyadic Applied BioSolutions ("Dyadic"), a global biotechnology company producing precision-engineered, animal-free proteins and enzymes across life science, food & nutrition, and bioindustrial markets, and BRIG BIO (official legal entity The Protein Collective B.V.), a Netherlands-based developer of next-generation recombinant dairy ingredients, today announced the signing of a Development and Commercialization Agreement to jointly develop and commercialize recombinant bovine alpha-lactalbumin.

This partnership combines Dyadic's innovation capabilities with BRIG BIO's expertise in dairy and medical nutrition, with the goal of advancing scalable, cost-effective production of animal-free alpha-lactalbumin for early life, active, healthy aging, and medical nutrition markets. Together, the companies aim to accelerate commercialization timelines, support commercially viable production, enhance market affordability, and expand global access to sustainable proteins with comparable functional properties to traditional dairy proteins.

Under the terms of the agreement, BRIG BIO will fully fund the development program and receive a global commercial license to Dyadic's production strains capable of producing alpha-lac developed in the Dapibus™ fungal expression system, and Dyadic will receive access and milestone payments and long-term shared revenue participation tied to commercial sales in addition to co-marketing and sales rights.